CANTAB explicit memory is less impaired in addicted schizophrenia patients.

scientific article published in October 2005

CANTAB explicit memory is less impaired in addicted schizophrenia patients. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1016/J.BANDC.2005.04.002
P698PubMed publication ID15913868
P5875ResearchGate publication ID7827633

P50authorStéphane PotvinQ34567371
Luc NicoleQ55722389
Emmanuel StipQ60510270
Alain LesageQ60603258
P2093author name stringOlivier Lipp
Roch-Hugo Bouchard
Pierre Lalonde
Antoinette Prouteau
Catherine Briand
P433issue1
P921main subjectschizophreniaQ41112
P304page(s)38-42
P577publication date2005-10-01
P1433published inBrain and CognitionQ4955810
P1476titleCANTAB explicit memory is less impaired in addicted schizophrenia patients.
P478volume59

Reverse relations

cites work (P2860)
Q34530176BRIEF REPORT: THE IMPACT OF ALCOHOL AND CANNABIS MISUSE ON COGNITION AMONG INDIVIDUALS WITH SCHIZOPHRENIA.
Q51969760Cannabis abuse is associated with decision-making impairment among first-episode patients with schizophrenia-spectrum psychosis.
Q50993509Cannabis and cognitive performance in psychosis: a cross-sectional study in patients with non-affective psychotic illness and their unaffected siblings.
Q37643444Cannabis use and cognition in schizophrenia
Q47945952Cognitive functioning associated with stimulant use in patients with non-affective psychosis, their unaffected siblings and healthy controls
Q38401669Comorbid substance abuse and neurocognitive function in recent-onset schizophrenia
Q38124448Comorbid substance use disorder in schizophrenia: a selective overview of neurobiological and cognitive underpinnings
Q47739996Effects of Extended Cannabis Abstinence on Cognitive Outcomes in Cannabis Dependent Patients with Schizophrenia vs Non-Psychiatric Controls
Q37340922Effects of early psychosocial deprivation on the development of memory and executive function
Q44346792Impulsivity and opioid drugs: differential effects of heroin, methadone and prescribed analgesic medication.
Q36577094Inferior performance on selected neuropsychological tests in abstinent schizophrenia patients who have used cannabis.
Q58597807Inhibition, shifting and updating in relation to psychometric intelligence across ability groups in the psychiatric population
Q43872699Lifetime cannabis use and cognition in patients with schizophrenia spectrum disorders and their unaffected siblings.
Q36959030Naturalistic follow-up of co-morbid substance use in schizophrenia: the West London first-episode study
Q33762494Neurocognitive functioning of individuals with schizophrenia: using and not using drugs
Q39577163Predictors of community functioning in schizophrenia and substance use disorder patients
Q35091697Subjective and Objective Cognitive Dysfunction in Schizophrenia - is there a Link?
Q36591245Susceptibility of the adolescent brain to cannabinoids: long-term hippocampal effects and relevance to schizophrenia
Q34531537The Cannabis Pathway to Non-Affective Psychosis may Reflect Less Neurobiological Vulnerability
Q33641039The impact of cannabis use on cognitive functioning in patients with schizophrenia: a meta-analysis of existing findings and new data in a first-episode sample
Q37061404The neural correlates of mental rotation abilities in cannabis-abusing patients with schizophrenia: an FMRI study
Q36965847The neuropsychology of cannabis and other substance use in schizophrenia: review of the literature and critical evaluation of methodological issues
Q36370752Visual memory of meaningless shapes in children and adolescents with autism spectrum disorders
Q51952571Working memory and depressive symptoms in patients with schizophrenia and substance use disorders.

Search more.